Bayer's MRI Contrast Agent Gadovist Could Get "Lower-Risk" Designation
This article was originally published in The Pink Sheet Daily
Executive Summary
But the sponsor will have to convince an FDA advisory committee that the drug's unusual dosing will not cause medication errors in a crowded class.